Recombinant Biotinylated Human CD47 Protein, His,Avitag™, 25 µg

Background
Leukocyte surface antigen CD47 is also known as Antigenic surface determinant protein OA3, Integrin-associated protein (IAP) and Protein MER6. CD47 contains 1 Ig-like V-type (immunoglobulin-like) domain. CD47 is very broadly distributed on normal adult tissues. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins and plays an important role in memory formation and synaptic plasticity in the hippocampus by similarity. CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. CD47 Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation.

Source
Recombinant Biotinylated Human CD47, His,Avitag(CD7-H82E9) is expressed from human 293 cells (HEK293). It contains AA Gln 19 - Pro 139 (Accession # Q08722-3).
Predicted N-terminus: Gln 19

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 16.9 kDa. The protein migrates as 32-44 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 24 months in lyophilized state;
-70^°C for 12 months under sterile conditions after reconstitution.

Bioactivity
Please refer to poduct data sheet.

Clinical and Translational Updates

(1) "Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications"
Wang, Wang, Jiang et al
Cancer Lett (2024)
(2) "Immunomodulatory Peptides as Vaccine Adjuvants and Antimicrobial Agents"
Hemmati, Saeidikia, Seradj et al
Pharmaceuticals (Basel) (2024) 17 (2)
(3) "The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment"
Zhuang, Zhou, Qiu et al
Cancers (Basel) (2024) 16 (4)
Showing 1-3 of 2652 papers.